VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
Industry, Sector and Symbol
Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone646 650 1351
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees44
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions
What is VolitionRX's stock symbol?
VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."
How were VolitionRX's earnings last quarter?
VolitionRX Ltd (NYSEAMERICAN:VNRX) announced its quarterly earnings data on Monday, August, 12th. The medical research company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01. View VolitionRX's Earnings History.
When is VolitionRX's next earnings date?
What price target have analysts set for VNRX?
2 equities research analysts have issued 1 year price objectives for VolitionRX's shares. Their predictions range from $5.00 to $6.00. On average, they anticipate VolitionRX's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price. View Analyst Price Targets for VolitionRX.
What is the consensus analysts' recommendation for VolitionRX?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VolitionRX.
Has VolitionRX been receiving favorable news coverage?
Media headlines about VNRX stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. VolitionRX earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for VolitionRX.
Are investors shorting VolitionRX?
VolitionRX saw a increase in short interest in August. As of August 31st, there was short interest totalling 83,300 shares, an increase of 36.6% from the July 31st total of 61,000 shares. Based on an average trading volume of 112,900 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.4% of the company's stock are sold short. View VolitionRX's Current Options Chain.
Who are some of VolitionRX's key competitors?
What other stocks do shareholders of VolitionRX own?
Who are VolitionRX's key executives?
VolitionRX's management team includes the folowing people:
- Dr. Martin Charles Faulkes, Exec. Chairman (Age 75)
- Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 48)
- Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 63)
- Dr. Jason Bradley Terrell, Chief Medical Officer (Age 39)
- Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 48)
Who are VolitionRX's major shareholders?
VolitionRX's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Morgan Stanley (0.25%), Ladenburg Thalmann Financial Services Inc. (0.08%) and Leisure Capital Management (0.04%). Company insiders that own VolitionRX stock include Cameron John Reynolds, Guy Archibald Innes and Martin Charles Faulkes. View Institutional Ownership Trends for VolitionRX.
Which major investors are selling VolitionRX stock?
Which major investors are buying VolitionRX stock?
VNRX stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley and Ladenburg Thalmann Financial Services Inc.. Company insiders that have bought VolitionRX stock in the last two years include Cameron John Reynolds, Guy Archibald Innes and Martin Charles Faulkes. View Insider Buying and Selling for VolitionRX.
How do I buy shares of VolitionRX?
Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is VolitionRX's stock price today?
One share of VNRX stock can currently be purchased for approximately $4.77.
How big of a company is VolitionRX?
What is VolitionRX's official website?
How can I contact VolitionRX?
The medical research company can be reached via phone at 646 650 1351.
MarketBeat Community Rating for VolitionRX (NYSEAMERICAN VNRX)
MarketBeat's community ratings are surveys of what our community members think about VolitionRX and other stocks. Vote "Outperform" if you believe VNRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
